Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
STSTAAR Surgical Company logo

STAAR Surgical Company (STAA)

NASDAQ Global Market · Currency in USD
$22.61 ▲ +0.12 (+0.53%)
At close: Oct 23, 4:00 PM ET. Market closed.
$22.61 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$22.49
Open
$22.47
Day's Range
$22.29 – $22.66
52 Week Range
$15.59 – $35.87
Volume
345,181
Avg. Volume
898,504
Market Cap
$1.13B
Beta (5Y Monthly)
1.18
PE Ratio (TTM)
282.63
EPS (TTM)
$0.08
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$30.89

Profile: STAAR Surgical Company

Sector
Healthcare
Industry
Medical - Instruments & Supplies
Full-time employees
921
CEO
Warren Foust
Website
staar.com

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate $0.05 · Revenue est. $78.74M
DateEst.Actual
Aug 12, 2026$0.22$0.16Miss
May 13, 2026$0.05$0.38Beat
Mar 3, 2026$0.18-$0.20Miss
Nov 5, 2025$0.18$0.46Beat
Aug 6, 2025-$0.56-$0.34Beat
May 7, 2025-$0.59-$0.52Beat

Analyst view

Consensus price target
$30.89 ▲ +36.6%
Range $23.00 – $40.00
Rating: Hold
Buy 31% · Hold 56% · Sell 13%

Get free alerts on STAA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.